Xconomy New York — New York biotech has historically lagged behind more established life sciences hubs like Boston and San Francisco, but collaborations between its research institutions have helped the city start to move forward. Another step in that direction was taken this morning, with the launch of what’s being called Bridge Medicines.
Bridge is a drug discovery company formed via a partnership between two local venture firms (Bay City Capital, Deerfield Management), three research centers (Memorial Sloan Kettering Cancer Center, Rockefeller University, Weill Cornell Medical College), and one pharmaceutical company (Takeda).
